Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
Status:
Terminated
Trial end date:
2017-06-28
Target enrollment:
Participant gender:
Summary
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment
regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor
(PI)-based antiretroviral therapy (ART). This study compared three alternative co-treatment
options among participants in high TB endemic resource-constrained settings, in which one
co-treatment option explores if an additional anti-HIV drug needs to be used when patients
are being treated with a PI together with rifabutin-based anti-TB treatment.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)